JP Morgan Maintains Overweight on Immunocore Hldgs, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Immunocore Holdings (NASDAQ:IMCR) and raises the price target from $60 to $70.
March 21, 2024 | 5:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on Immunocore Holdings and raises the price target from $60 to $70.
The upgrade in the price target by a reputable financial institution like JP Morgan, especially with a maintained Overweight rating, is a strong positive signal to the market. This suggests a bullish outlook on the stock by the analyst, which could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100